Results 271 to 275 of about 103,961 (275)

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

New England Journal of Medicine, 2019
James Larkin, Jean-Jacques Grob, Piotr Rutkowski   +2 more
exaly  

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

New England Journal of Medicine, 2019
Matthew D Hellmann, Luis Paz-Ares, Reyes Bernabé   +2 more
exaly  

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

Lancet, The
Elena Elez, Lars Henrik Jensen, Yann Touchefeu   +2 more
exaly  

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

New England Journal of Medicine, 2017
Jedd D Wolchok, Piotr Rutkowski, Jean-Jacques Grob   +2 more
exaly  

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Lancet, The
Leonardo G Da Fonseca, Hong-Jae Chon, Matsatoshi Kudo   +2 more
exaly